The FTA, the Berbatt committee, if anybody's watched this before, Pfizer representatives,

scientists march in there and they present their data.

And that's usually kind of held up as like, this is gold standard data from the company,

making the product, and then the FDA moves forward with that.

So when FDA gave the licensing, the EUA to Pfizer's mRNA coba shot, they gave them some stipulations.

They said, we're going to give these EUA, but you have to do some stuff for us.

You have to make sure that you continue studying any of these issues that come up in populations.

Obviously, not a perfect system.

It's already out in the world giving to hundreds of millions of people, and they're not even

getting their shoes on and start studying this.

But putting that aside, they had homework to do, and that was given to them by the FDA.

One of them was this, and this was directly from their 2021 approval letter from the FDA.

And it says they need to study, they may have a substudy to perspectively assess the

incidences of subclinical myocarditis, following the third dose of a common already as their

Pfizer vaccine.

And a subset of participants, 16 to 30 years of age, very important, because we know that's

where a lot of the myocarditis is happening, especially in males.

Now, if you look at the bottom there in the highlighted spot, final report submission,

December 31, 2022, they should have this report in their hands.

And by the way, the vaccine is just completed on June 30, 2022.

So they're giving them all that time to finish it up.

Yeah, yeah, exactly.

...